This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Shisan Bao
University of Sydney
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: To determine whether IL-31, IL-32 and IL-33 can be used as biomarkers for the detection of gastric cancer (GC), via evaluating the correlations between IL-31, IL-32 and IL‑33 expression and clinicopathological parameters of GC patients.
Methods: Tissue array (n=180) gastric specimens were utilised. IL-31, IL-32 and IL-33 in GC and non-GC tissues were detected immunohistochemically. The correlations between IL-31, IL-32 and IL-33 in GC and severity of clinicopathological parameters were evaluated. Survival curves were plotted using the Kaplan-Meier/Cox regression. IL-31, IL-32 and IL-33 in circulation were detected by ELISA.
Results: IL-31, IL-32 and IL-33 were all lower in GC than that in adjacent non-GC gastric tissue (p all <0.05). IL-33 in peripheral blood of GC patients was significantly lower than that of healthy individuals (1.50 ± 1.11 vs 9.61 ± 8.00 ng/ml) (p<0.05). Decreased IL-31, IL-32 and IL-33 in GC were observed in younger patients (<60 years), and IL-32 and IL-33 were lower in female patients (p all <0.05). Higher IL-32 correlated with longer survival in two GC subgroups: T4 invasion depth and TNM I-II stage. Univariate/multivariate analysis revealed that IL-32 is an independent prognostic factor for GC within the T4 stage subgroup. Circulation IL-33 was significantly lower in GC patients than healthy people (p <0.05).
Conclusions: Our findings provide new insights into the roles of IL-31, IL-32 and IL-33 in carcinogenesis of GC and demonstrate their relative usefulness as prognostic markers for GC. The underlying mechanism of IL-31, IL-32 and IL-33 in GC is further discussed.
Keywords
diagnosis and therapy, gastric cancer, immune cell interactions
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
- Table1.pdf
- Table2.pdf
- Table3.pdf
- supplementaryfigures.pdf
Supplementary Figure 1 Correlation of IL-31, IL-32 and IL-33 expression with clinicopathological parameters of tumour size, lymph node metastasis, tumour differentiation and tumour invasion depth subtypes of GC IL-31, IL-32 and IL-33 all have no correlations with any clinicopathological parameters of tumour size, lymph node metastasis, tumour differentiation and tumour invasion depth subtypes of GC. Supplementary Figure 2 Correlation of IL-31, IL-32 and IL-33 expression with clinicopathological parameter of TNM subtype of GC and IL-31 expression with gender subtype of GC IL-31, IL-32 and IL-33 all have no correlations with clinicopathological parameter of TNM subtype of GC. Moreover, no significant differences were observed in IL-31 with gender of GC. Supplementary Figure 3 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients Kaplan-Meier survival analysis of IL-31, IL-32 and IL-33 for prognosis of GC in tumour invasion depth T3, TNM III- IV stage and yes/no lymph node metastasis subtypes of GC patients. Supplementary Figure 4 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients Kaplan-Meier survival analysis of IL-31, IL-32 and IL-33 for prognosis of GC subtypes of tumour differentiation and size. Supplementary Figure 5 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients Kaplan-Meier survival analysis of IL-31, IL-32 and IL-33 for prognosis of GC subtypes of age and gender of tumour patients. Supplementary Figure 6 Survival analysis of combination of IL-31, IL-32 and IL-33 for prognosis of GC Kaplan-Meier survival analysis of combinations of IL-31, IL-32 and IL-33 for prognosis of GC
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
The most recent version of this article is available here.
No community comments so far
No comments provided
Version 1
Posted 21 Dec, 2020
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Shisan Bao
University of Sydney
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
The most recent version of this article is available here.
No community comments so far
No comments provided
Version 1
Posted 21 Dec, 2020
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The most recent version of this article is available here.
Background: To determine whether IL-31, IL-32 and IL-33 can be used as biomarkers for the detection of gastric cancer (GC), via evaluating the correlations between IL-31, IL-32 and IL‑33 expression and clinicopathological parameters of GC patients.
Methods: Tissue array (n=180) gastric specimens were utilised. IL-31, IL-32 and IL-33 in GC and non-GC tissues were detected immunohistochemically. The correlations between IL-31, IL-32 and IL-33 in GC and severity of clinicopathological parameters were evaluated. Survival curves were plotted using the Kaplan-Meier/Cox regression. IL-31, IL-32 and IL-33 in circulation were detected by ELISA.
Results: IL-31, IL-32 and IL-33 were all lower in GC than that in adjacent non-GC gastric tissue (p all <0.05). IL-33 in peripheral blood of GC patients was significantly lower than that of healthy individuals (1.50 ± 1.11 vs 9.61 ± 8.00 ng/ml) (p<0.05). Decreased IL-31, IL-32 and IL-33 in GC were observed in younger patients (<60 years), and IL-32 and IL-33 were lower in female patients (p all <0.05). Higher IL-32 correlated with longer survival in two GC subgroups: T4 invasion depth and TNM I-II stage. Univariate/multivariate analysis revealed that IL-32 is an independent prognostic factor for GC within the T4 stage subgroup. Circulation IL-33 was significantly lower in GC patients than healthy people (p <0.05).
Conclusions: Our findings provide new insights into the roles of IL-31, IL-32 and IL-33 in carcinogenesis of GC and demonstrate their relative usefulness as prognostic markers for GC. The underlying mechanism of IL-31, IL-32 and IL-33 in GC is further discussed.
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
- Table1.pdf
- Table2.pdf
- Table3.pdf
- supplementaryfigures.pdf
Supplementary Figure 1 Correlation of IL-31, IL-32 and IL-33 expression with clinicopathological parameters of tumour size, lymph node metastasis, tumour differentiation and tumour invasion depth subtypes of GC IL-31, IL-32 and IL-33 all have no correlations with any clinicopathological parameters of tumour size, lymph node metastasis, tumour differentiation and tumour invasion depth subtypes of GC. Supplementary Figure 2 Correlation of IL-31, IL-32 and IL-33 expression with clinicopathological parameter of TNM subtype of GC and IL-31 expression with gender subtype of GC IL-31, IL-32 and IL-33 all have no correlations with clinicopathological parameter of TNM subtype of GC. Moreover, no significant differences were observed in IL-31 with gender of GC. Supplementary Figure 3 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients Kaplan-Meier survival analysis of IL-31, IL-32 and IL-33 for prognosis of GC in tumour invasion depth T3, TNM III- IV stage and yes/no lymph node metastasis subtypes of GC patients. Supplementary Figure 4 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients Kaplan-Meier survival analysis of IL-31, IL-32 and IL-33 for prognosis of GC subtypes of tumour differentiation and size. Supplementary Figure 5 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients Kaplan-Meier survival analysis of IL-31, IL-32 and IL-33 for prognosis of GC subtypes of age and gender of tumour patients. Supplementary Figure 6 Survival analysis of combination of IL-31, IL-32 and IL-33 for prognosis of GC Kaplan-Meier survival analysis of combinations of IL-31, IL-32 and IL-33 for prognosis of GC
Loading...